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Edited by Richard MaraisAbstract Connector enhancer of KSR (CNK) proteins have been
proposed to act as scaﬀolds in the Ras-MAPK pathway. In this
work, using in vivo bioluminescence resonance energy transfer
(BRET) assays and in vitro co-immunoprecipitation, we show that
hCNK1 interacts with the active form of Rho A (G14V) proteins.
The domain of hCNK1 that allows binding to Rho proteins in-
volves the C-terminal PH domain. Overexpression of hCNK1
does not aﬀect the actin cytoskeleton and does not modify the
appearance of stress ﬁbers in cells overexpressing a constitutively
active form of RhoA. In contrast, hCNK1was able to signiﬁcantly
decrease the RhoA-induced transcriptional activity of the serum
response element (SRE) without eﬀect on the Ras-induced SRE
activation. These results identify hCNK1 as a speciﬁc partner of
Rho proteins both in vitro and in vivo and suggest a role of hCNK1
in the signal transduction of Rho proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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element1. Introduction
The Ras and Rho family of small GTPases play a critical
role in transducing extracellular signals controlling cell prolif-
eration, diﬀerentiation and survival [1–3]. Ras and Rho pro-
teins control these pathways by binding to eﬀector proteins
through its eﬀector loop regions, which are thought to activate
speciﬁc signaling cascades. Among the best characterized eﬀec-
tors of Ras proteins are the Raf protein kinase family, the
phosphatidylinositol 3-kinase and the Ral-GDS exchange fac-
tor for the small GTPase Ral, which control the activation of
the mitogen-activated protein kinase (MAPK) pathway, actin
cytoskeleton, vesicular traﬃcking and play a major role in
controlling both cell proliferation and diﬀerentiation [4–6].Abbreviations: BRET, bioluminescence resonance energy transfer;
CNK, connector enhancer of KSR; MAPK, mitogen-activated protein
kinase; PBS, phosphate buﬀered solution; PFA, paraformaldehyde;
SRE, serum response element
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Cdc42) control intracellular signaling processes through bind-
ing to a number of eﬀector proteins such as the WASP family
of proteins, PAK, PAR 6, among others, that in turn modulate
the actin cytoskeleton, transcriptional outputs, cell prolifera-
tion and diﬀerentiation [7,8].
Although the Ras/Rho signaling has been extensively stud-
ied in a number of systems, our understanding of how signals
are regulated through these small GTPases is still far from
complete. Genetic analysis in Drosophila and C. elegans has
shown the existence of a number of scaﬀold proteins such as
KSR1, dCNK, Sur-8, or MP1, to play a role in Ras-MAPK
pathway [9–14]. The dCNK protein (named for connector en-
hancer of KSR) was identiﬁed as an enhancer of a Drosophila
dominant-negative KSR mutant [14]. dCNK was found to
cooperate strongly with activated RAS when coexpressed in
the Drosophila eye and seems to be required for normal cell
proliferation and diﬀerentiation [14,15]. By virtue of its modu-
lar primary structure, CNK potentially could couple multiple
eﬀector responses; these domains include a sterile alpha motif
(SAM) domain, a PDZ domain, two proline-rich (potential
SH3-binding) domains, and a C-terminal pleckstrin homology
(PH) domain; such domains are found in many proteins in-
volved in signaling and suggest further interactions of CNK
with other proteins and small molecules. Structural compari-
sons of dCNK have identiﬁed three separate genes in humans:
CNK1 and CNK2 share conserved domain structure with
dCNK; two separate genes on chromosome 6, CNK3A and
CNK3B share only partial domain homology with Drosophila
CNK [16]. dCNK1 interacts with Raf through its C-terminal
portion and its expression is required for insulin-dependent
Raf activation [17–19]. It is not known whether hCNK1 also
binds other proteins in the Ras signaling pathway and the
biochemical relationship of hCNK1 to small GTPases is
unknown.
Since CNK proteins have been proposed to act as scaﬀolds
in the Ras-MAPK pathway, we sought to explore the possibil-
ity that CNK1 could interact with members of the small
GTPase family of Ras and/or Rho proteins in vivo. In order
to test these putative interactions in a systematic way using in-
tact cells, we established bioluminescence resonance energy
transfer (BRET) assays. This protein–protein interaction assay
is based on energy transfer from a bioluminescent donor
(Luciferase) to a ﬂuorescent acceptor protein (GFP) [20–22].
BRET assays have been used recently in the discovery of aublished by Elsevier B.V. All rights reserved.
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receptors, the characterization of integrins and TGFb receptor
interaction or dimerization of STAT3 [21–24]. BRET assays
have a number of advantages in comparison to more conven-
tional approaches such as immunoprecipitation or yeast two-
hybrid systems; speciﬁcally, BRET is quantitative and allows
in vivo detection of molecular interactions in a native cellular
environment with post-transcriptional modiﬁcations and is
unaﬀected by small variations in expression levels.
In this work, we show the ability of hCNK1 to interact with
members of the Rho family of small GTPases. We show that
this interaction occurs both in vitro and in vivo and maps
the domains in CNK1 responsible for this interaction. Further-
more, we identify a role of CNK1 in mediating Rho-induced
transcriptional activation independent of cytoskeletal reorga-
nization. These results suggest that CNK1 act as a novel eﬀec-
tor scaﬀold able to coordinate and/or mediate Rho/Ras
signaling activities.2. Materials and methods
2.1. Reagents and plasmids
Dulbeccos modiﬁed Eagles (DME) medium, restriction enzymes for
molecular biology and PCR primers were purchased from Invitrogen
(Carlsbad, CA). Fetal calf serum and L-glutamine were obtained from
Invitrogen (Carlsbad, CA). Leupeptin and aprotinin were products
from Sigma (St. Louis, MO). The full length human CNK1 was poly-
merase chain reaction-ampliﬁed and subcloned in a modiﬁed
pcDNA3.1-Renilla Luciferase vector (Invitrogen, Carlsbad, CA),
CMV-GFP2 vector as C-terminal or N-terminal fusion proteins (Per-
kin–Elmer, Boston, MA) or in HA or Flag epitope-tagged expression
vectors. In a similar manner, amino-terminal fragments (SAM: aa 1–
74; CRIC: aa 75–165; SAM-CRIC: aa 1–165; PDZ: aa 166–314;
SAM-CRIC-PDZ: aa 1–314) and carboxyl terminal fragments of
hCNK1 (Pro-PH: aa 315–713; PH: aa 384–504) were generated by
polymerase chain reaction with use of reverse primers containing stop
codons at the desired locations, and the cDNAs were subcloned into
either pcDNA3.1-Luciferase, CMV-GFP2 or pCMV-myc vectors.
cDNAs encoding for Rho proteins were obtained from the Guthrie
cDNA Resource Center (Sayre, PA) and PCR ampliﬁed for subcloning
in the pcDNA3.1-Luciferase or CMV-GFP2 vectors. The primer se-
quences are available upon request. All the constructs were veriﬁed
by DNA sequencing using the Sanger dideoxy termination method
adapted to the Applied Biosystems model 373S Automated DNA
Sequencer.2.2. Cell culture and transient transfection procedures
Cells were kept at logarithmic growth phase in DME supplemented
with 10% heat-inactivated fetal calf serum and 2 ml L-Glutamine in a
humidiﬁed atmosphere containing 5% CO2. The NH2-terminal or
COOH-terminal-tagged hCNK1 constructs were transiently transfec-
ted in HEK293 cells using the Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA). The ratio of epitope-tagged luciferase constructs and
GFP fusion cDNAs was 1:3. Cells were harvested 48 h after transfec-
tion in Dulbeccos-PBS, and immunoprecipitation, BRET or luciferase
assays were performed as described below.2.3. Immunoprecipitation and Western blotting
Subconﬂuent HEK293 cells grown in a 10-cm dish and cotransfected
with the indicated plasmids were serum-starved for 12 h after 48 h of
transfection. Cells were then washed with ice-cold phosphate-buﬀered
saline (PBS), incubated in 1 ml of lysis buﬀer (50 mM Tris, 25 mM
NaCl, 1% Nonidet P-40, and a protease inhibitor mixture, pH 7.5)
for 15 min at 4 C, and scraped from the plate. The lysates were clar-
iﬁed by centrifugation at 15 000 · g for 15 min at 4 C. 2 lg of either
polyclonal anti-myc or anti-ﬂag antibody (M2, Sigma) or an irrelevant
antibody pre-adsorbed on protein A-Sepharose beads was incubated
with 1 ml of lysate for 2 h at 4 C. Beads were washed four times with1 ml of lysis buﬀer and 2 times with PBS, resuspended, boiled in 50 ll
of 2X Laemmli sample buﬀer, and loaded for SDS–PAGE. For
Western blotting, electrophoresed proteins were transferred onto nitro-
cellulose and probed with the respective primary antibodies. Peroxi-
dase-conjugated goat anti-rabbit or goat anti-mouse secondary
antibodies (Amersham, NJ) were incubated at a 1:5000 dilution for 1
h at room temperature and antibody complexes were detected by en-
hanced chemi-luminescence (ECL Plus; Amersham, NJ) on XAR-5
ﬁlm (Kodak, NY).
2.4. Bioluminescence resonance energy transfer assays
Forty-eight hours post-transfection, HEK-293 cells were detached
with PBS/EDTA and washed twice in PBS. Approximately 50 000 cells
per well were distributed in a 96-well microplate (Perkin–Elmer, Bos-
ton, MA). The DeepBlue coelenterazine substrate (Perkin–Elmer, Bos-
ton, MA) was added at a ﬁnal concentration of 5 lM, and readings
were collected by using a Victor2 microplate reader (Perkin–Elmer,
Wellesley, MA) that allows for the detection of signals using ﬁlters
at 410 and 515 nm wavelengths. Expression of fusion proteins in
HEK293 cells was checked by Western blot, GFP ﬂuorescence and
luciferase assays.
2.5. Immunoﬂuorescence microscopy
NIH3T3 cells were seeded in glass coverslips and co-transfected with
hCNK1 constructs using the method described above. The cells were
then ﬁxed with 4% PFA for 30 min and permeabilized with 0.05%
Tween 20. hCNK1 and Rho proteins were detected with the respective
epitope tagged antibodies and an Alexa-conjugated goat anti-rabbit
antibody (Molecular Probes, Eugene, OR). Actin cytoskeleton was
visualized with rhodamine-phalloidin. All images were acquired with
a scientiﬁc-grade, cooled, charge-coupled camera using a microscopy
system from Zeiss. Imaging processing was carried out with the image
processing software ImagePro (Media Cybernetics, Silver Spring,
MD).
2.6. Luciferase reporter assays
HEK293 cells (35-mm dishes) were transfected with 0.2 lg of SRE-
luciferase reporter plasmid containing 0.5 kilobases of the human SRE
promoter [25], 0.01 lg of pRL-CMV (Promega), and the indicated
amount of the reporter vector. Cells were then lysed by reporter lysis
buﬀer and luciferase activities were measured with a luminometer
(EG&G). To determine the luciferase activities, a Dual-Luciferase Re-
porter System (Promega, Madison, WI) was used. To normalize the
transfection eﬃciency, pRL-CMV vector yielding constitutive expres-
sion of Renilla luciferase was co-transfected with the SRE. Luciferase
reporter gene vector, and dual luciferase activities were measured
according to the manufacturers protocol.3. Results and discussion
To establish a protocol of detection of CNK1 interactions in
intact cells, we tested if the known interaction of CNK1 with
Raf proteins [14,18] could be detected using the BRET system.
HEK293 cells were transfected with vectors encoding Lucifer-
ase Raf-BXB [4], GFP-CNK1 or empty vectors; 48 h post-
transfection the cells were detached from the culture wells
and subjected to BRET analysis. As shown in Fig. 1A (left pa-
nel), we were able to detect a signiﬁcant signal of interaction
(90–100% over the controls) in cells expressing both Luciferase
Raf-BXB and GFP-CNK1. Western blots showing similar lev-
els of protein expression of the transfected constructs are
shown beside (Fig. 1A, right panels). Further validation of
BRET analysis in CNK1 interactions was conﬁrmed by a po-
sitive signal of interaction between CNK1 and RASSF1A (see
Supplementary Fig. 1) as we recently reported [16].
After validation of our BRET protocol, we performed a ser-
ies of cotransfections in HEK293 cells using GFP-hCNK1 as
bait and constitutively active small GTPases fused to luciferase.
Fig. 1. CNK1 interaction with members of the small GTPase family of Rho proteins in intact cells. (A) BRET assay of CNK1 interaction with Raf
proteins. Forty-eight hours post-transfection, HEK-293 cells were detached with PBS/EDTA and washed twice in PBS. Approximately 50 000 cells
per well were distributed in a 96-well microplate, the DeepBlue coelenterazine substrate was added and readings were collected by using a Victor2
microplate reader as described in Section 2 (upper panel). Protein expression in aliquots of the same cell preparation was tested by Western blot
analysis using antibodies against GFP or Luciferase (middle and lower panels). (B) CNK1 speciﬁc interaction with Rho A proteins. The indicated
members of the Rho GTP-binding proteins were transiently transfected in HEK293 cells and tested for interaction 48 h later in BRET assays. Protein
expression was analyzed by Western blot as described above. (C) Coimmunoprecipitation assays of CNK with Rho proteins. An expression construct
of CNK1 carrying an N-terminal myc epitope tag was transfected into HEK293 cells and its expression was analyzed by Western blotting using a
monoclonal antibody against the N-terminal c-myc epitope tag. HEK293 cell lysates expressing myc epitope-tagged CNK were immunoprecipitated
with the respective antibodies and the immunoprecipitated pellets were subjected to Western blot analysis with antibodies directed against the Flag
epitope tag attached to small GTPases.
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acts speciﬁcally with GTP bound Rho A proteins and in less ex-
tent with Rho C. The other members of the Rho GTP-binding
proteins are unable to show any signiﬁcant signal of interac-
tion as compared with the vector alone. In order to conﬁrm
these interactions in an independent assay, we tested these
interactions in a series of coimmunoprecipitation assays
(Fig. 1C). HEK293 cells transiently co-transfected with myc
epitope-tagged CNK1 and Flag-RhoAV14, Flag-RacV12, Flag
Cdc42V12 or corresponding empty vector were immunoprecip-
itated with Flag antibodies and the pellets were subjected to
Western blot analysis with antibodies directed against the
myc epitope tag for detection of CNK1. As shown in Fig. 1C
(upper panel), CNK1 was able to co-immunoprecipitate with
RhoAV14, whereas the closely related members Rac or
Cdc42 were unable to be co-immunoprecipitated. A similar
level of expression was demonstrated by Western blotting using
a monoclonal antibody against the respective epitope tags
(Fig. 1C, lower panels). These results demonstrate that NK1
interacts with Rho proteins both in vivo and in vitro; and
additionally validate the use of BRET assays to the study of
protein–protein interactions in intact cells.
To determine whether the Rho-CNK1 interaction is depen-
dent on a speciﬁc activation state of Rho, we performed
co-immunoprecipitation assays using either the wild-type, a
constitutively active or a dominant negative form of RhoA.
Fig. 2A shows that only constitutive active RhoA is able toco-precipitate with CNK1. The in vivo interaction of these
proteins was conﬁrmed in BRET assays using a panel of pro-
teins belonging to the Rho subfamily. None of the wild type
forms of Rho proteins was able to give a positive signal of
interaction with the exception of RhoH that is known to be
locked in a constitutively active form [26] and the active form
of Rho C that gives a moderate interaction signal with hCNK1
(see also Fig. 1B). Similar levels of expression of GFP-CNK1
and Luciferase fused to various Rho proteins are shown in
upper and bottom panels of Fig. 2B. Several experiments indi-
cate that BRET interaction signals were due to a direct, and
speciﬁc interaction between hCNK1 and Rho proteins, and
not due to non-speciﬁc oligomerization through the fused
(GFP or luciferase) molecules or an indirect interaction medi-
ated by the cortical actin or tubulin cytoskeleton. The BRET
signal was observed at a wide range of expression levels, and
was constant at DNA concentrations spanning a 20-fold
range, indicating that the signal was not due to high proteins
levels after transient overexpression (see Supplementary Fig.
2); BRET was detected when the cellular cytoskeleton was dis-
rupted by treating the cells with vinblastin (1 mM), latrunculin
B (1 · 106 M) or after the disruption of macromolecular
aggregates in endocytic vesicles by treatment with high concen-
trations of EGTA (50 lM, Fig. 2C). On the other side, the
BRET assay is sensitive to close proximity and orientation of
the molecules involved in the interaction, with an optimal sig-
nal achieved with an intermolecular distance between 50 and
Fig. 2. Speciﬁc interaction of CNK1 with the active form of RhoA. (A) Co-immunoprecipitation assays using either the wild-type, a constitutively
active or a dominant negative form of RhoA and c-myc epitope-tagged CNK1. After 48 h of expression, cells were lysed and immunoprecipitated
with anti-HA antibodies followed by Western blot with anti-myc antibodies. Total cellular expression of CNK and Rho proteins is shown in the
middle and lower panels. (B) In vivo interaction of CNK with members of the subfamily of Rho proteins. Forty-eight hours post-transfection with
the indicated constructs, HEK-293 cells were detached from the cell culture wells and subjected to BRET and Western blot analysis as described
above. (C) Eﬀect of microaggregation inhibitors on the Rho-CNK interaction. After 48 h of expression, Luc-RhoA V14 and GFP-CNK expressing
cells were treated for 30 min before BRET assays with EGTA (50 lM) to inhibit aggregation by endocytosis or inhibitors of actin (latrunculin B,
1 · 106 M) or tubulin (vinblastine, 1 mM) polymerization.
Fig. 3. Domains of interaction of CNK with RhoA and its eﬀects on actin cytoskeleton. (A) BRET assays to determine the domain of interaction in
CNK that allows for binding to Rho proteins. The indicated GFP-CNK1 deletion mutants (SAM: aa 1–74; CRIC: aa 75–165; SAM-CRIC: aa 1–165;
PDZ: aa 166–314SAM-CRIC-PDZ: aa 1–314; Pro-PH: aa 315–713) containing sequences predicted to be protein interaction domains were co-
transfected with luciferase-RhoAV14. Forty-eight hours after transfection, the cells were detached and subjected to BRET analysis (left panel).
Protein expression in aliquots of the same cell preparation was tested by Western blot using antibodies against GFP or Luciferase (right panel) as
described in Section 2. (B) CNK localization and eﬀects on actin cytoskeleton. CNK1 full length or deletion mutants were transfected in NIH3T3
cells seeded in glass coverslips. After 48 h of expression, the cells were then ﬁxed with 4% PFA for 30 min and permeabilized with 0.05% Tween 20.
CNK1 proteins were detected with the respective epitope tagged antibodies and an Alexa-conjugated goat anti-rabbit antibody (Molecular Probes,
Eugene, OR). Actin cytoskeleton was visualized with rhodamine-phalloidin (1 lM). Bar, 20 lm.
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Fig. 4. Functional analysis of CNK on SRE transcriptional activation. (A,B) HEK293 cells (35-mm dishes) were transfected with 0.2 lg of SRE-
luciferase reporter plasmid containing 0.5 kilobases of the human SRE promoter [19], 0.01 lg of pRL-CMV (Promega), and 1 lg of the indicated
CNK constructs. Cells were then lysed by reporter lysis buﬀer and luciferase activities were measured with a luminometer. Average of three
independent experiments are shown. Error bars indicate S.E.M.
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hCNK1 with RhoA reﬂects a close proximity and probably a
direct contact between these molecules.
To determine the domain of interaction in hCNK1 that al-
lows for binding to Rho proteins, several hCNK1 deletion mu-
tants were constructed containing sequences predicted to be
contact sites involved in protein–protein interactions. Together
with the wild type form of hCNK1, the transfection of GFP-
epitope tagged form of the C-terminal end of hCNK1 contain-
ing the c-terminal proline rich region and a PH domain (aa
315–729) was able to interact with RhoA V14 (Fig. 3A). The
deletion mutants containing the SAM, CRIC, SAM and
CRIC, SAM, CRIC and PDZ, or the PDZ domain alone were
unable to show any type of interaction despite similar levels of
protein expression (Fig. 3A, middle and lower panels). Consis-
tent with these results, co-immunoprecipitation assays per-
formed with an hCNK1 mutant lacking the PH domain were
unable to interact with RhoAV14; on the other hand, the
expression of the hCNK1 PH domain alone gave a potent sig-
nal of interaction in BRET assays (see Supplementary Fig. 3).
Taken together, these results suggest a critical role of hCNK1
PH domain in the interaction with Rho proteins.
The expression of GFP epitope-tagged hCNK1 allowed us
to analyze its cellular distribution. hCNK1 wild type and the
CNK1 mutant containing the ProPH domains appear to form
cytosolic clusters, whereas the other mutants show a diﬀuse
cytosolic distribution (Fig. 3B, upper panel). Although the
identity of the subcellular structures harboring hCNK1 has
not been elucidated, it is known that active forms of Rho pro-
teins are recruited to intracellular membranes, belonging to
Golgi, endoplasmic reticulum and secretory granules; in con-
trast to inactive forms that are diﬀuse in the cytosol [27,28].
These results suggest that CNK1 and RhoA may form active
signaling complexes in membrane structures inside the cell.
Since a variety of studies have shown that GTP bound forms
of Rho can induce potent eﬀects on actin polymerization and
transcriptional activation [1,25,29–32], we tested hCNK1 ef-
fects on stress ﬁber formation in the absence or presence of
activated RhoA. As shown in Fig. 3B (lower panel), neither
hCNK1 nor any of its deletion mutants were able to aﬀect
the cytoskeletal architecture or to modify the appearance of
stress ﬁbers in NIH3T3 cells stimulated with serum or over-
expressing a constitutively active form of RhoA V14. These re-sults suggest that the functional eﬀect of CNK1 on RhoA
signaling is independent of actin reorganization. In contrast,
the transfection of hCNK1 was able to signiﬁcantly decrease
the Rho-induced transcriptional activity of a luciferase gene
under the control of the SRE element (Fig. 4A). This eﬀect
is speciﬁc for the Rho pathway, as the same construct had
no eﬀect on the Ras-induced SRE activation. Furthermore,
the transfection of the C-terminal or N-terminal domains of
hCNK1 was able to signiﬁcantly decrease the activation of
RhoA-induced SRE, whereas the Pro-PH domain of hCNK,
but not the SAM-CRIC-PDZ domain, was able to inhibit
the Ras-induced SRE activation. These results suggest that
both the N and the C-terminal domain of hCNK1 are criti-
cal for a full activation of SRE under conditions of RhoA
activation.
The cross-talk between Ras and Rho signaling pathways in
transformation, proliferation and motility has been reported
by a number of investigators [2,33–36]. Thus, the elucidation
of signaling proteins that interact with Ras-Raf-MAPK path-
way will be critical for understanding cellular growth control.
Transformation by oncogenic Ras requires the function of the
Rho family GTPases, RhoA and Rac1; this cross-talk depends
on the kinetics and duration of Ras activity and is cell type-
and Ras subtype-speciﬁc. In a Swiss-3T3 model in which Ras
and Rho signaling pathways interact to promote transforma-
tion, Ras-transformed cells have elevated levels of RhoA-
GTP, and downregulation of ROCK1 and Rho-kinase which
correlates with decreased expression of the cell cycle inhibitor
p21/Waf1 and repression of Rho-dependent stress ﬁber forma-
tion [33]. In intestinal epithelial cells, coexpression of both
activated Raf and RhoA induces transformation, tumor
growth in nude mice, and resistance to growth inhibition by
TGFb; in contrast, single transfectants showed none of these
characteristics [36].
During the preparation of this manuscript, an independent
study showing hCNK1 interaction with RhoA was published
[37]. In this study, the overexpression of either hCNK wild
type or a mutant unable to bind to Rho or depletion of
endogenous hCNK1 leads to inhibition of Rho-induced gene
expression. In our experiments, we also observe inhibition of
RhoA-induced SRF activation after hCNK1 overexpression.
Although the molecular mechanisms of hCNK1 regulation
are unknown, the scaﬀold nature of hCNK1 may explain its
M.A. Lopez-Ilasaca et al. / FEBS Letters 579 (2005) 648–654 653critical role on downstream signaling at conditions of both
overexpression or depletion. It is possible that overexpression
of ProPH domain of hCNK that binds to Rho could act as
a dominant negative molecule inhibiting the interaction with
endogenous hCNK1, whereas the SAM-CRIC-PDZ mutant
could sequester a critical endogenous eﬀector. Additionally,
in a direct comparison of Rho and Ras-induced transcriptional
activation, the SAM-CRIC-PDZ mutant did not aﬀect the
SRE activation induced by Ras, suggesting that by controlling
a speciﬁc transcriptional arm of SRE activation, hCNK1
might aﬀect the balance of transcriptional outputs between
Rho and Ras. Taken together, our results identify hCNK1
as a speciﬁc partner of Rho proteins both in intact cells and
in vitro and suggest a critical role of hCNK1 in the signal
transduction to transcriptional activation dependent of Rho
proteins.
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